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Venlafaxine is not usually associated with risk of orthostatic hypotension. A 65-year-old US Caucasian female taking 225mg/day of
venlafaxine extended-release developed symptomatic orthostatic hypotension. The systolic and diastolic blood pressure dropped
by 25 and 18mm Hg, respectively, from supine position to standing position within 3 minutes. The patient was otherwise healthy
and the orthostatic hypotension resolved with venlafaxine discontinuation. This was a probable venlafaxine adverse drug reaction
according to the Naranjo scale. This case contributes to the scarce literature that indicates that clinicians need to be aware that
occasionally venlafaxine can induce clinically significant orthostatic hypotension, particularly in geriatric patients. Our patient did
not have orthostatic hypotension when she was taking venlafaxine at 60 years of age in higher venlafaxine doses (300mg/day)
but developed this adverse drug reaction when venlafaxine was restarted at the geriatric age. This case indicates that a history of
prior tolerance to venlafaxine does not guarantee tolerance after 65 years of age. If a clinician decides to use venlafaxine in geriatric
patients, the clinician should warn the patient about the risk of orthostatic hypotension and consider very slow titration and low
doses.
1. Introduction
The Consensus Committee of the American Autonomic
Society and the American Academy of Neurology [1] defined
orthostatic hypotension as “a reduction of systolic blood
pressure (BP) of at least 20mm Hg or diastolic BP of at
least 10mmHgwithin 3minutes of standing.”This consensus
definition has recently been updated with minor changes [2].
Orthostatic hypotension can be an adverse drug reac-
tion (ADR) to several antidepressants and antipsychotics.
These drugs can cause orthostatic hypotension during the
first few weeks of treatment but usually tolerance develops.
Thus, the risk for hypotension is one of the reasons that
slow titration is recommended for some of these drugs.
Orthostatic hypotension is usually explained by the alpha-
1
antagonistic properties of some antidepressants and antipsy-
chotics [3]. Among antidepressants, several of the tricyclic
antidepressants (TCAs) are potent alpha-
1
antagonists, but
venlafaxine is usually considered to be lacking in antagonist
properties at these receptors [3]. Articles focused on ven-
lafaxine cardiovascular ADRs describe venlafaxine as being
prone to cause hypertension, but it is not considered to
cause orthostatic hypotension [4, 5]. The blockade of the
noradrenergic reuptake transporter explains why venlafaxine
can frequently cause hypertension [5].
We described one case of venlafaxine-induced orthostatic
hypotension that was carefully assessed using the Naranjo
scale [6], one of the most frequently used ADR scales. This
case contributes to the scarce literature that indicates that
clinicians need to be aware that occasionally venlafaxine can
induce clinically relevant orthostatic hypotension, particu-
larly in geriatric patients. Moreover, our patient did not have
orthostatic hypotension with prior venlafaxine treatment but
developed this ADR when she reached geriatric age.
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2. Case Presentation
A 65-year-old US Caucasian female had a history ofDSM-IV-
TRmajor depressive disorder and anxiety disorder NOS. She
had no significant medical problems. For three years (from
57 to 60 years of age), she was treated with 300mg/day of
venlafaxine extended-release (150mg twice a day) and 10mg
of zolpidem at night. She had no ADRs, but, due to a change
in the coverage of her medical insurance, she was switched
from venlafaxine to citalopram (20mg/day). After 6 months,
she asked her psychiatrist to switch her antidepressant due to
uncontrolled anxiety. For the next 2 years (from60 to 62 years
of age), she tried duloxetine (60mg/day), but, after observing
a worsening of tics, she was switched back to citalopram
(20mg/day) and she was stable for 3 years. At age 65, after
worsening of her tics, the patient requested her psychiatrist
(VC) to switch her to venlafaxine extended-release.
The psychiatrist started venlafaxine extended-release
75mg/day and recommended gradual titration to the target
dose of 300mg/day (150mg administered twice a day) over
5-week duration. Citalopram was tapered off in 7 days. At
5-week followup, when the patient had been on venlafaxine
for 4 weeks, including a dose of 225mg/day for 14 days, the
patient complained of “lightheadedness” and “blacking out,”
particularly when rising from supine to standing position.
This worsened with the increased dose of venlafaxine. The
patient had no other medical problems; her only other
medication was zolpidem at the same dose (10mg at night)
for the last 2 years. The psychiatrist established that the
patient met criteria for orthostatic hypotension [1, 2] since
the systolic and diastolic BP dropped by 25 and 18mm Hg,
respectively, from supine position to standing positionwithin
3 minutes. The systolic BP dropped from 135 to 110mm Hg
while the diastolic dropped from 94 to 76mm Hg. She was
tapered off venlafaxine in 7 days and restarted on citalopram.
One week later (3 days after the complete discontinuation of
venlafaxine), the patient reported a complete resolution of the
symptoms. In a follow-up visit (3 weeks after the complete
resolution of symptoms), she did not have any significant
change in her orthostatic blood pressure; her systolic BP
dropped by 8mm Hg (from 118 to 110mm Hg) while the
diastolic dropped by 7mm Hg (from 69 to 62mm Hg) from
supine position to standing positionwithin 3minutes.TheBP
drop no longer met the criteria for orthostatic hypotension.
The patient’s psychiatrist (VC) scored the probability that
this ADR was explained by venlafaxine treatment using the
Naranjo scale [6]. She obtained a score of 8 (range up to 9)
that indicated that the ADR was probably associated with
venlafaxine treatment.
3. Discussion
The Naranjo scale [6] indicated that the ADR was probably
associated with venlafaxine treatment. A PubMed search
using the terms “venlafaxine and orthostatic hypotension”
provided a case report by Duggal et al. [7] and a geriatric
study by Johnson et al. [8]. Duggal et al. described a
clinically relevant orthostatic hypotension case in a 46-year-
old Indian male with two episodes of falls on 225mg/day
of venlafaxine extended-release [7]. They did not provide a
score using the Naranjo scale. With the available published
information, one of us (VC) obtained a score of 7 indicating
a probable venlafaxine ADR. Johnson et al. [8] described
an open-label 12-week study on 72 geriatric patients taking
venlafaxine. They measured orthostatic changes in 47 of
their patients weekly. There were 38 patients who had no
orthostatic changes at baseline before starting venlafaxine;
50% of them had orthostatic changes at least twice during
the 12 weeks. More importantly, of the 30 patients who did
not endorse dizziness at baseline, 8 developed mild dizziness
during venlafaxine treatment. Although other cardiovas-
cular ADRs were associated with venlafaxine discontinua-
tion, no patient discontinued venlafaxine due to orthostatic
changes and/or dizziness. It was recommended that patients
with orthostatic changes drink more fluids and go from
supine to standing position slowly. Thus, this recommen-
dation appeared sufficient to avoid symptomatic orthostatic
changes.
Duggal et al. [7] provided a reference for a relevant
Australian venlafaxine study [9] not included in PubMed.
Alderman and Wiese [9] described a retrospective review of
13 of 18 (72%) mainly geriatric patients who unexpectedly
had orthostatic hypotension during titration. Contributing
factors included (1) history of hypertension, or ischaemic
heart disease, and (2) intake of antihypertensives, or nitrate
vasodilators.
As antidepressants typically cause orthostatic hypoten-
sion by blocking alpha-
1
adrenergic receptors [3], it is not
unreasonable to suspect that this case may be also explained
by venlafaxine blockade of these receptors. In vitro studies
usually state that venlafaxine has no affinity for alpha-
1
adren-
ergic receptors [3], but the affinity of venlafaxine metabolites
for these receptors has never been studied, to the best of
our knowledge. Some cases of lethal venlafaxine overdoses
were associated with refractory hypotension [10], indicating
that something associated with venlafaxine treatment may
cause, in special circumstances, clinically relevant alpha-
1
adrenergic blockade.
Our case is interesting in the sense that our patient did not
develop orthostatic hypotension when she previously took
venlafaxine (from 57 to 60 years of age), but she developed it
when she reached 65 years of age. Geriatric age is frequently
associated with clinically relevant changes in pharmacokinet-
ics [11] and pharmacodynamics [12]. The decrease in renal
drug clearance may be the most important factor related to
venlafaxine, since geriatric patients tend to have 50% higher
plasma venlafaxine concentrations [13]. Geriatric age is
associated with pharmacodynamic changes that are not well
understood [12]. According to Trifiro´ and Spina [12], one of
the most evident pharmacodynamic geriatric changes is the
selective dysfunction of the homeostatic systems that control
the alpha-
1
adrenergic receptor system, whichmediates acute
changes in vasoconstriction. Thus, it can be postulated that
during the last 5 years, our patient progressively developed
a decrease in renal clearance and dysfunction of the alpha
1
-
adrenergic receptor vascular system, which explained her
orthostatic changes on venlafaxine at 65 years of age, despite
no symptoms when she was younger.
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In spite of the fact that venlafaxine is not expected to
cause orthostatic hypotension, in some patients orthostatic
hypotension may not only be clinically relevant but can be
associatedwith substantial risks, particularly of falls. Our case
is unique since the patient did not have orthostatic hypoten-
sion with prior venlafaxine treatment. However, when the
patient was restarted on venlafaxine at 65 years of age, she
was no longer able to tolerate lower venlafaxine doses than
those she had taken 5 years earlier. Our case contributes to
the literature that indicates the substantial risk of orthostatic
hypotension in geriatric patients treated with venlafaxine. If
a clinician decides to use venlafaxine in geriatric patients, the
clinician should warn the patient about the risk of orthostatic
hypotension and consider very slow titration and low doses.
A history of prior tolerance to venlafaxine does not imply
tolerance after 65 years of age.
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